TiE My Story Featuring Sarvajna Dwivedi

About the Event

How do you crack the biopharmaceutical technology success code! Every life sciences entrepreneur recognizes the numerous opportunities offered by this industry and also the challenges of selling into this market. Learn how a company was created to develop differentiated therapeutics for respiratory disease conditions prevalent worldwide, including chronic obstructive pulmonary disease (COPD). Join us as TiE SV Charter Member Sarvajna Dwivedi shares his story on how Pearl Therapeutics, a company he co-founded in 2006, went from a small startup to be part of a global innovation-driven biopharmaceutical company. AstraZeneca acquired Pearl in July 2013 for a total potential acquisition cost of up to $1.15 billion to strengthen its respiratory products portfolio. Pearl has an experienced team of inhalation product development experts with proven track record in the development and commercialization of innovative respiratory products. Pearl’s lead product candidates are a fixed-dose dual combination bronchodilator, PT003 (glycopyrronium and formoterol fumarate), and a triple combination PT010 (budesonide, glycopyrronium and formoterol fumarate) for the treatment of COPD, a disease with over 200 million patients worldwide. As an AstraZeneca group company, Pearl remains focused on development of these and other product candidates. Join us to hear this inspiring talk from an amazingly successful entrepreneur, ask all your questions, learn from his successful experiences and connect with other aspiring entrepreneurs at TiE office on Tuesday, November 5, 2013. About Sarvajna Dwivedi and Pearl Sarvajna Dwivedi, Ph.D., Co-Founder & Chief Scientific Officer, Pearl Therapeutics, Inc., is a pharmaceutical scientist with 21 years of experience in various therapeutic classes, dosage forms, and devices from discovery to commercialization, including the development of multi-billion $ respiratory product brands at Glaxo. Sarvajna co-founded Pearl, assembled its management team, and put together its operating plan to develop differentiated inhaled combinations for globally prevalent respiratory illnesses. Pearl raised $167.5M in three rounds of venture capital between 2007 and 2012, and progressed a dual drug combination into Phase III clinical testing in less than six years. Pearl was acquired by AstraZeneca for $1.15B in June 2013, and continues to thrive as an independent group company within AstraZeneca. Pearl is a 2010, 2012 and 2013 TiE50 life sciences award winner, a 2013 Red Herring North America top 100 finalist, a 2013 Excellence in Drug Delivery Award winner, a FierceBiotech 2011 Fierce Top15 company, and one of FierceBiotech’s 2010 Top 15 Venture Capital Deal maker. Prior to his industrial career, Sarvajna conducted award-winning research in Pharmaceutical Sciences at the University of British Columbia in Vancouver, Canada, and was trained in basic pharmaceutics at Banaras Hindu University in Varanasi, India. TiE Host: Naveen Bisht, Chair, My Story and Chair, Programs/Board Member, TiE Silicon Valley Schedule: 6:00 PM - Registration, Dinner & Networking 7:00 PM - Program 8:15 PM - Q & A 9:00 PM- Adjourn